Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bone infarction24.04.05.011; 15.02.04.0310.000052%Not Available
Mitochondrial cytopathy14.11.02.0080.000052%Not Available
Xanthogranuloma16.21.04.005; 01.13.04.005; 15.09.01.0090.000052%Not Available
Pulmonary cavitation22.01.02.0220.000035%Not Available
Bone marrow oedema15.02.01.005; 01.05.01.0190.000035%Not Available
Small intestinal haemorrhage24.07.02.019; 07.12.03.0020.000087%
Non-alcoholic steatohepatitis14.08.04.024; 09.01.07.0350.000070%Not Available
Insulin-requiring type 2 diabetes mellitus14.06.01.009; 05.06.01.0090.000035%Not Available
Cardiac ventricular thrombosis02.11.01.008; 24.01.05.0060.000070%Not Available
Splenic lesion01.09.02.0170.000035%Not Available
Secondary immunodeficiency10.03.03.0090.000070%Not Available
Intervertebral disc space narrowing15.10.01.0070.000052%Not Available
Necrotising oesophagitis07.04.05.0060.000035%Not Available
Mediastinal haemorrhage24.07.01.075; 22.09.03.0080.000035%
Cubital tunnel syndrome17.09.02.0090.000035%Not Available
Neuroendocrine carcinoma16.24.01.007; 05.08.01.0110.000035%Not Available
Ciliary body disorder06.06.06.0070.000052%Not Available
Aortic dilatation24.03.04.0070.000070%Not Available
Abdominal compartment syndrome07.11.01.017; 24.04.09.0090.000035%Not Available
Thalamus haemorrhage24.07.04.033; 17.08.01.0620.000035%Not Available
Paraneoplastic syndrome16.32.01.0090.000035%Not Available
Cotard's syndrome19.10.01.0030.000052%Not Available
Haemorrhagic ascites09.01.05.007; 07.07.02.003; 24.07.02.0320.000035%Not Available
Choroidal neovascularisation24.03.07.011; 06.10.03.0040.000087%Not Available
Diffuse alveolar damage22.01.01.0190.000035%Not Available
Cerebellar haematoma24.07.04.022; 17.08.01.0450.000035%Not Available
Foot deformity15.10.03.0050.000122%Not Available
Hip deformity15.10.03.0080.000035%Not Available
Pyelocaliectasis20.01.06.0110.000035%Not Available
Leukaemia recurrent16.01.03.005; 01.10.03.0050.000052%Not Available
The 31th Page    First    Pre   31 32 33 34 35    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene